

Creutzfeldt-Jakob disease & Laboratory Tests

MICHAEL FISCHER, MD, MPH & TM
 EPIDEMIOLOGIST - PRION DISEASE SURVEILLANCE
 EMERGING AND ACUTE INFECTIOUS DISEASE BRANCH
 INFECTIOUS DISEASE CONTROL UNIT
 TEXAS DEPARTMENT OF STATE HEALTH SERVICES

Case Definition For Possible & Probable sCJD

Possible sCJD

Dementia or Rapid Progressive Dementia with at least 2 clinical signs:

1. **Myoclonus** (e.g., twitches)
2. **Cerebellar** or visual symptoms (e.g., "drunken" walking, incoordination, depth misperception)
3. **Pyramidal** or **subcortical symptoms** (e.g., weakness, tremors, Parkinson's disease like walking)
4. **Akinetic mutism** (lack of voluntary speech & movement)

Probable sCJD

Satisfies possible sCJD definition **AND** at least 1 of the following:


- ▶ 1. **Periodic sharp wave complexes (PSWCs)** on electroencephalogram (EEG) (looks at brain waves)
- ▶ 2. Elevated protein **14-3-3** in spinal fluid and disease duration < 2 years
- ▶ 3. Abnormal findings in **basal ganglia** or at **least two cortical** (e.g., outside) **regions** on specific sequences on brain **MRI**

Cellular vs Pathogenic Forms of the prion protein

PrPC = Cellular (Normal) Prion Protein
 PrPSc = Pathogenic (Abnormal) Prion Protein

Prion Protein Aliases:

PrNP, ASCR, AIPHP, CD230, CJD, GSS, KURU, PRIP, PrP, PrP27-30, PrP33-35C, PrPc, p27-30



A healthy protein that your body normally produces

3-Dimensional Conformation: High proportion of α -helices

A misfolded protein that kills brain cells

3-Dimensional Conformation: Increased proportion of β -pleated sheets

Comparison of findings by Prion disease

Features	CJD Type				
	sCJD	vCJD	ICJD	GSS	FFI
Mean age at onset	60-70 yrs	28 yrs	60 yrs	60 yrs	50 yrs
Duration of illness	5 mos	14 mos	6 mos	5 yrs	14 mos
Predominant clinical features	Rapid cognitive decline, myoclonus	Early psychiatric symptoms, then cognitive decline	Similar to sCJD	Cerebellar signs	Insomnia
MRI findings	60%-70% have hyperintensities in basal ganglia or cortex	Pulvinar sign in 90%	Basal ganglia & cortical hyperintensities	Rarely abnormal	Non-specific atrophy
EEG findings	PSWCs in 60%-70%	PSWCs negative	PSWCs in 75%	Rarely positive	Rarely positive
14-3-3 status	Positive in 90%	Positive in 50%	Similar to sCJD	Negative	Rarely positive
Genetics	MM1 most common (70%)	MM in 100%	PRNP mutation	P102L is most common mutation	D178N mutation

Prion Diseases of Humans

- | | |
|--|------------------------------------|
| 1. Sporadic Creutzfeldt-Jakob disease (sCJD) | Sporadic Disease |
| 2. Sporadic Fatal Insomnia (sFI) | |
| 3. Variably Protease-sensitive Prionopathy (VPSPr) | |
| 4. Familial Creutzfeldt-Jakob disease (fCJD) | Genetic/Inherited/Familial Disease |
| 5. Fatal Familial Insomnia (FFI) | |
| 6. Gerstmann-Sträussler-Scheinker syndrome (GSS) | Acquired Disease |
| 7. Iatrogenic Creutzfeldt-Jakob disease (iCJD) | |
| 8. Variant Creutzfeldt-Jakob disease (vCJD) | |
| 9. Kuru | |

Typical Features of sCJD by Subtype (Polymorphism [129th codon] & Glycoform)

TABLE 1. Genetic subtypes of sCJD and typical features

Features	sCJD Subtype				
	MM1/MV1	VV2	MV2	MM2	VV1
Mean age at onset	70 yrs	65 yrs	60 yrs	67 yrs	44 yrs
Duration of illness	4 mos	6 mos	18 mos	14 mos	21 mos
Predominant clinical features	Rapid cognitive decline w/ myoclonus	Progressive ataxia in absence of myoclonus	Prominent ataxia & cognitive decline	Rapidly progressive dementia w/ myoclonus	Psychiatric changes, slowly progressive dementia
MRI findings	70% MRI hyperintensities in basal ganglia or cortex	70% hyperintensities in basal ganglia, 45% in thalamus	70% hyperintensities in basal ganglia, + pulvinar sign	Cortical changes in 25%, rare basal ganglia involvement	Frequent cortical hyperintensities, rare basal ganglia involvement
EEG findings	PSWCs in 80%	PSWCs in 10%	Similar to VV2	PSWCs in 42%	PSWCs negative
14-3-3 status	95% positive	80% positive	Similar to VV2	91% positive	Positive in nearly all cases
Percentage of sCJD case	60%-70%	Approximately 15%	Approximately 10%	Approximately 5%	Approximately 1%

Supportive Tests for Prion Disease

Labs:

- ▶ **Tau Protein** - CSF
- ▶ **14-3-3 Protein** - CSF
- ▶ **Real Time-Quaking Induced Conversion (RT-QuIC)** - CSF

Imaging:

- ▶ Magnetic Resonance Imaging (MRI)
- ▶ Electroencephalogram (EEG)

Diseases that may have positive 14-3-3 and/or Tau protein CSF Test Results

- ▶ Herpes simplex & other viral encephalitides
- ▶ Recent stroke
- ▶ Subarachnoid hemorrhage
- ▶ Hypoxic brain hemorrhage
- ▶ Metabolic encephalopathy after barbiturate intoxication
- ▶ Glioblastoma
- ▶ Carcinomatous meningitis from small-cell lung cancer
- ▶ Paraneoplastic encephalopathy
- ▶ Corticobasal degeneration

Supportive Lab Criteria

(sporadic, genetic, & iatrogenic CJD)

- ▶ **CSF - 14-3-3 protein:** (Mayo Clinic)
 - ▶ ELISA reported as elevated or above normal limits (>1.5 pg/ml) OR
 - ▶ Western blot (WB) reported positive (NPDpsc)

If 14-3-3 protein is the only supportive test used in determining classification, then duration of illness must be < 2 years.
- ▶ **CSF - 1-Tau (Total-Tau) protein:** Positive (>1149 pg/ml) (NPDpsc)
- ▶ **CSF - RT-QuIC:** Positive (NPDpsc)
- ▶ **EEG**
 - ▶ Reported as "typical of" or "consistent with" sporadic CJD OR
 - ▶ Presence of generalized bi- or triphasic "periodic sharp wave complexes" (PSWC); frequency = 1-2/s.

No time limit on duration of illness.
- ▶ **MRI**
 - ▶ High signal abnormalities in the basal ganglia (caudate nucleus and/or putamen) on diffusion-weighted imaging (DWI) or fluid attenuated inversion recovery (FLAIR).


No time limit on duration of illness.

Confirmatory Path Criteria

(sporadic, genetic, & iatrogenic CJD)

- ▶ Diagnosis by standard neuropathological techniques AND/OR
 - ▶ Immunohistochemistry (IHC) AND/OR
 - ▶ Western blot (WB) AND/OR
 - ▶ Presence of scrapie-associated fibrils from biopsy or autopsy obtained brain tissue
- (NPDpsc)
- ### Genetic Testing – a blood test
- (genetic CJD)
- The NPDpsc offers genetic testing at no cost if there is a 1° degree relative diagnosed or confirmed of CJD (any type)

Real-Time Quaking Induced Conversion (RT-QuIC)




CSF Protein Markers (Tau protein & 14-3-3 protein)

- ▶ Non-specific for disease
- ▶ Elevated in presence of active neuron destruction due to any cause
- ▶ False positive due to blood in the CSF
 - ▶ Red or pink appearing CSF
 - ▶ Yellow/Orange CSF (xanthochromia)
 - ▶ RBC counts >500 cells per μ L
 - ▶ WBC counts >10 cells per μ L
- ▶ Clinical correlation is required
 - ▶ Positive results without clinical findings consistent with CJD are do not carry weight in the diagnosis of CJD
- ▶ Sensitivity: 14-3-3 > Tau; Specificity: Tau > 14-3-3;

PrP^{Sc} Capture, Amplification of PrP^{Sc}, & Quantitative Analysis via Fluorescence (ThT)

Christina D. Orru; Jason M. Wilham; Sarah Vascellari; Andrew G. Hughson; Byron Caughey; Prion 2012, 6, 147-152.
 DOI: 10.4161/pri.19430
 Copyright © 2012 Landes Bioscience



Diagnostic performance of 2nd generation CSF RT-QuIC, 14-3-3, & T-Tau; prospective cohort

CSF Samples from sCJD Cases

	UK		Japan		Australia	
	RT-QuIC	14-3-3	RT-QuIC	14-3-3	RT-QuIC	14-3-3
Sensitivity	89%	94%	83%	72%	88%	88%
Specificity	99%	63%	100%	95%	100%	71%


Neuropathology (n)	Prion Positive (n)	Sporadic CJD (n)	Genetic CJD (n)
79	65	63	2
RT-QuIC			
Dx Specificity (%)	100	100	100
Dx Sensitivity (%)	94	94.7	100
14-3-3			
Dx Specificity (%)	40	40	40
Dx Sensitivity (%)	79.1	80.7	100
T-Tau > 1149 pg/ml			
Dx Specificity (%)	73.3	73.3	73.3
Dx Sensitivity (%)	94	93	100

Disease	Gene	Mutation
Prion diseases	PRNP	Point mutations & octapeptide repeats
Alzheimer's disease	APP	Point mutations
	PS1	Point mutations
	PS2	Point mutations
Parkinson's disease	SNCA	Point mutations
	PARKIN	Point mutations
Frontotemporal dementia	TAU	Point mutations
Pick's disease	TAU	Point mutations, deletions
Amyotrophic lateral sclerosis	sod1	Point mutations
Huntington's disease	hd	Polyglutamine expansions
Spinocerebellar ataxia	Type 1	SCA1
	Type 2	SCA2
	Machado-Joseph disease	SCA3
		Polyglutamine expansions

In the near future... Less invasive procedures?

Olfactory mucosa (OM) brushing procedure

Olfactory mucosa (OM) brushing procedure



Prevalence of Neurodegenerative Diseases in the United States in 2000.

TABLE 1. PREVALENCE OF NEURODEGENERATIVE DISEASE IN THE UNITED STATES IN 2000.

Disease	No. of Cases	No. per 100,000*
Prion disease	400	<1
Alzheimer's disease	4,000,000	1450
Parkinson's disease	1,000,000	360
Frontotemporal dementia	40,000	14
Pick's disease	5,000	2
Progressive supranuclear palsy	15,000	5
Amyotrophic lateral sclerosis	20,000	7
Huntington's disease	20,000	11
Spinocerebellar ataxias	12,000	4

The RT-QuIC test carries the potential as a definitive diagnostic test for neurodegenerative diseases with amyloid pathology

*Data are based on a population of approximately 275 million in 2000. Pruisner SB. N Engl J Med 2001;344:1516-1526.

Typical EEG findings for sporadic Creutzfeldt-Jakob disease (sCJD)

Periodic sharp wave complexes (PSWCs)



Conditions that may mimic EEG findings typical for sporadic CJD

- ▶ Alzheimer disease
- ▶ Lewy body disease
- ▶ Binswanger disease
- ▶ AIDS dementia hypernatremia
- ▶ Multiple cerebral abscesses
- ▶ MELAS syndrome
- ▶ Post-anoxic encephalopathy
- ▶ Hyperammonemia
- ▶ Hyperparathyroidism
- ▶ Hypo- and hypernatremia
- ▶ Hypoglycemia
- ▶ Hepatic encephalopathy
- ▶ Baclofen, mianserin, metrizamide and lithium toxicity

The presence of **periodic sharp-wave complexes (PSWCs)** is reported to have a sensitivity of **67%** and a **specificity of 86%** for sCJD, the remaining cases being noted to have only nonspecific slow-wave abnormalities.

MRI – “Cortical Ribbing”

Case courtesy of Dr Chris Obenaus, Radiopaedia.org, rID: 16320

Normal MRI of the Brain; Structures and Findings Suggestive of Prion Disease

Hyperintensity of the **posterior thalamus** might be seen in both sCJD and vCJD.

In the proper clinical context, the **bilateral hyperintensity of the posterior thalami** (the “**pulvinar**” or “**hockey stick**” sign) is **highly specific for vCJD**.

The **putamen, external capsule, internal capsule, caudate hyperintensities** might be seen in sCJD.

In sCJD, cortical ribboning is frequently seen, this is not typical of vCJD.

Brain MRI, FLAIR imaging, axial view – Findings Seen in vCJD

A) Normal FLAIR image: Thalamus

- Isointense or slightly hypointense *relative to* the putamen

B) Pulvinar sign of vCJD; FLAIR image

- Marked, symmetrical hyperintensity of the pulvinar (posterior) thalamic nuclei

C) “Hockey-stick” sign of vCJD -FLAIR image

- Symmetrical pulvinar and dorsomedial thalamic nuclear hyperintensity
- This combination gives a characteristic “hockey-stick” appearance
- In a study of 98 Confirmed vCJD cases, the sign was present in 93% of cases by FLAIR imaging

Donald A. Collie et al. AJNR Am J Neuroradiol 2003;24:1560-1569 ; ©2003 by American Society of Neuroradiology

Conditions with thalamic hyperintensity on MRI

A. Causes of thalamic high signal (involving whole thalamus or other thalamic nuclei except pulvinar)

- Carbon monoxide poisoning
- Japanese Nipositu encephalitis
- Wernicke encephalopathy
- Bi-thalamic glioma
- Thala infarction

B. Causes of pulvinar and dorsomedial nuclear group hyperintensity

- Benign intracranial hypertension (BIH)
- Cat-scratch disease
- Alpers syndrome
- Post-infectious encephalitis

Normal sCJDMM1 sCJDMM2 Microscopic View of the Cerebral Cortex